Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $184,793 | 24 | 94.5% |
| Travel and Lodging | $3,767 | 19 | 1.9% |
| Unspecified | $3,640 | 1 | 1.9% |
| Food and Beverage | $2,310 | 33 | 1.2% |
| Honoraria | $940.00 | 1 | 0.5% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $151,675 | 40 | $0 (2023) |
| Merck Sharp & Dohme LLC | $18,115 | 23 | $0 (2024) |
| AstraZeneca UK Limited | $8,850 | 4 | $0 (2022) |
| Theravance Biopharma, Inc. | $5,282 | 5 | $0 (2018) |
| GlaxoSmithKline, LLC. | $4,642 | 2 | $0 (2023) |
| Biogen, Inc. | $3,640 | 1 | $0 (2018) |
| AstraZeneca AB | $2,250 | 1 | $0 (2023) |
| CSL Behring | $940.00 | 1 | $0 (2021) |
| Celgene Corporation | $56.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $525.00 | 1 | Merck Sharp & Dohme LLC ($525.00) |
| 2023 | $28,349 | 26 | Merck Sharp & Dohme LLC ($17,590) |
| 2022 | $11,108 | 3 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,608) |
| 2021 | $111,689 | 7 | Boehringer Ingelheim Pharmaceuticals, Inc. ($106,924) |
| 2020 | $12,790 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,265) |
| 2019 | $14,850 | 19 | Boehringer Ingelheim Pharmaceuticals, Inc. ($14,794) |
| 2018 | $8,922 | 6 | Theravance Biopharma, Inc. ($5,282) |
| 2017 | $7,219 | 12 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,126) |
All Payment Transactions
78 individual payment records from CMS Open Payments — Page 4 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $50.10 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2017 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $92.13 | General |
| 02/01/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Evaluating the Efficacy and Safety of BG00011 in Participants With Idiopathic Pulmonary Fibrosis | Biogen, Inc. | $3,640 | 1 |
About Dr. Naftali Kaminski, MD
Dr. Naftali Kaminski, MD is a Pulmonary Disease healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/09/2015. The National Provider Identifier (NPI) number assigned to this provider is 1376918870.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Naftali Kaminski, MD has received a total of $195,450 in payments from pharmaceutical and medical device companies, with $525.00 received in 2024. These payments were reported across 78 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($184,793).
Practice Information
- Specialty Pulmonary Disease
- Location New Haven, CT
- Active Since 12/09/2015
- Last Updated 12/09/2015
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1376918870
Products in Payments
- OFEV (Drug) $5,494
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in New Haven
Michael Imevbore, M.d, M.D
Pulmonary Disease — Payments: $271,586
Lauren Cohn, Md, MD
Pulmonary Disease — Payments: $166,306
Wassim Fares, Md, Msc, MD, MSC
Pulmonary Disease — Payments: $128,283
Carrie Redlich, Md, MD
Pulmonary Disease — Payments: $8,441
Dr. Sushil Gupta, M.d, M.D
Pulmonary Disease — Payments: $5,175
Dr. Kaiser Toosy, Md, MD
Pulmonary Disease — Payments: $3,778